Warm autoimmune hemolytic anemia management: first-line therapy?

Warm autoimmune hemolytic anemia management: first-line therapy?

• A. Corticosteroids
• B. Splenectomy
• C. Rituximab
• D. Plasmapheresis

Answer: (D)

Warm autoimmune hemolytic anemia is driven by IgG autoantibodies that coat red blood cells and trigger their destruction mainly in the spleen. The best starting therapy is corticosteroids, which suppress the immune response and reduce both autoantibody production and macrophage-mediated clearance of coated cells. Clinically, patients often begin to improve within one to two weeks as the hemolysis slows and the hemoglobin rises with tapering. Plasmapheresis is not used as first-line therapy because it rapidly removes antibodies from the plasma but doesn’t stop their production, and the effects are temporary with ongoing antibody generation and continued phagocytosis of coated red cells. It may be considered in severe, life-threatening hemolysis or as a bridge to other treatments, but it doesn’t provide durable control. Splenectomy is typically reserved for patients who relapse or require ongoing steroid treatment; by removing the primary site of splenic destruction, it can reduce hemolysis, but it doesn’t address ongoing autoantibody production. Rituximab, a B-cell–depleting therapy, is used for steroid-refractory or dependent cases and can provide durable remissions, though it’s not the first-line choice due to slower onset and greater consideration of risks.

Warm autoimmune hemolytic anemia is driven by IgG autoantibodies that coat red blood cells and trigger their destruction mainly in the spleen. The best starting therapy is corticosteroids, which suppress the immune response and reduce both autoantibody production and macrophage-mediated clearance of coated cells. Clinically, patients often begin to improve within one to two weeks as the hemolysis slows and the hemoglobin rises with tapering.

Plasmapheresis is not used as first-line therapy because it rapidly removes antibodies from the plasma but doesn’t stop their production, and the effects are temporary with ongoing antibody generation and continued phagocytosis of coated red cells. It may be considered in severe, life-threatening hemolysis or as a bridge to other treatments, but it doesn’t provide durable control.

Splenectomy is typically reserved for patients who relapse or require ongoing steroid treatment; by removing the primary site of splenic destruction, it can reduce hemolysis, but it doesn’t address ongoing autoantibody production. Rituximab, a B-cell–depleting therapy, is used for steroid-refractory or dependent cases and can provide durable remissions, though it’s not the first-line choice due to slower onset and greater consideration of risks.